Navigation Links
TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
Date:2/8/2013

LOS ANGELES, Feb. 9, 2013 /PRNewswire/ -- Product liability law firm TorkLaw continues to pursue litigation against St. Jude Medical on behalf of injured patients and their families.

In December 2011, the Food and Drug Administration issued a Class 1 recall for the St. Jude Medical Riata leads after many adverse events were being reported in patients. Studies showed that the leads which connect the heart defibrillator to the heart were failing due to insulation problems referred to as externalization.  A Class 1 Recall is the highest level recall that exists because the product poses a reasonable probability of serious adverse health consequences or death.

TorkLaw is now representing patients in fifteen states who have been affected by the recalled Riata leads and continues its ongoing investigation.  "We are speaking with patients from all over the country who have suffered from life-threatening injuries as a result of the defects found in St. Jude Medicals's heart devices," said Reza Torkzadeh , Senior Partner at TorkLaw.

The wires in the St. Jude Riata leads were found to protrude or perforate through the insulation resulting in lead failure, errant shocks, migration and other injuries.  Removal of leads is a very complex and potentially dangerous operation.   

"We are seeing a wide range of injuries caused by the defective leads.  All of these individuals have suffered a level of anxiety and pain that most of us will never understand," said Torkzadeh, who says his firm is committed to seeing that St. Jude is held accountable. 

The latest FDA investigation into St. Jude Medical was focused on the newer Durata leads also manufactured by St. Jude. In an official FDA warning letter to St. Jude Medical, dated January 10, 2013, the government agency cites St. Jude Medical for multiple manufacturing and quality control problems at their facility in Sylmar, California.

"The latest warning letter from the FDA raises a lot of red flags.  The FDA makes it very clear that their month-long inspection resulted in pinpointing the systematic failure of St. Jude Medical to follow approved manufacturing processes, proper monitoring, analysis, quality control and testing. That is not acceptable," said Torkzadeh.

TorkLaw is providing free legal consultations to those who have been affected by the St. Jude Medical heart defibrillator and Riata Leads.  Call today for a free consultation 888.222.8286.


'/>"/>
SOURCE The Torkzadeh Law Firm
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TorkLaw Accepting DePuy Hip Implant Cases
2. TorkLaw Accepting St. Jude Medical Device Cases
3. Medbox Responds to Unprecedented Rise in Stock Price
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Concord Medical Responds to Unusual Market Activity in its Stock
6. iMD Companies responds to shareholder questions
7. Icahn Responds To Forest Labs Board
8. Physician-Patient Alliance for Health & Safety: Addressing The Joint Commission Opioid Warnings Can Reduce Respiratory Depression and Improve Patient Safety in Hospitals
9. First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors
10. National Sleep Expert Issues Warning about Popping Pills to Replace Sleep
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 2017 , ... Miami native and local periodontist Dr. John Paul Gallardo ... imagined back in 1991 that this journey would have taken me into so many ... years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader ...
(Date:4/26/2017)... Pa. (PRWEB) , ... April ... ... division, which provides an agile ecosystem and domain expertise for sponsors and ... configurable randomization and trial supply management (RTSM) software platform. Bioclinica AGILE ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... agreement to be the preferred physical therapy provider for Derby City CrossFit, effective ... Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
Breaking Medicine News(10 mins):